Consequences of elevated luteinizing hormone on diverse physiological systems: use of the LHbetaCTP transgenic mouse as a model of ovarian hyperstimulation-induced pathophysiology.
Chronically elevated luteinizing hormone (LH) induces significant pathology in the LHbetaCTP transgenic mouse model, which uses the bovine gonadotropin alpha (alpha)-subunit promoter to direct transgene expression specifically to gonadotropes in the anterior pituitary. Previously, it was shown that female LHbetaCTP mice are infertile due to anovulation, develop granulosa cell tumors, and undergo precocious puberty from elevated LH and steroid hormones that fail to completely repress the alpha-subunit promoter. This chapter will discuss recent studies that further elucidate the impact of chronically elevated LH on diverse physiological systems. Granulosa cell tumors induced by elevated LH are strain dependent and prevented when transgenics are treated with human chorionic gonadotropin (hCG) surges. A granulosa cell tumor-associated transcriptome is generated, revealing several possible gene candidates for ovarian granulosa cell tumorigenesis. Primordial follicles in LHbetaCTP transgenics become depleted and oocytes exhibit increased rates of meiotic segregation defects, although meiotic competency is acquired normally. Anovulation can be rescued in transgenics by superovulation, though pregnancy fails at midgestation due to maternal factors. Uterine receptivity defects prevent implantation of normal embryos following induction of pseuodpregnancy. Transgenics develop Cushing-like adrenocortical hyperfunction with increased corticosterone production following induction of adrenal LH receptor expression. Elevated LH acts as a tumor promoter in the gonads and the adrenal gland, when expressed in conjunction with the inhibin-alpha SV40 transgene. Finally, chronic elevated LH promotes mammary tumorigenesis. The understanding of multiple clinical pathologies--including ovarian cancer, perimenopausal reproductive aging, premature ovarian failure, polycystic ovarian syndrome, Cushing's syndrome, and breast cancer--may be enhanced through further study of this useful transgenic mouse model.
Mann
Rachel J
RJ
Department of Pharmacology, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA.
Keri
Ruth A
RA
Nilson
John H
JH
D000375:Aging; D000818:Animals; D018997:Chorionic Gonadotropin, beta Subunit, Human / Q000235:genetics; D003480:Cushing Syndrome / Q000209:etiology / Q000503:physiopathology; D004195:Disease Models, Animal; D005260:Female; D007986:Luteinizing Hormone / Q000235:genetics / Q000378:metabolism*; D037101:Luteinizing Hormone, beta Subunit / Q000235:genetics; D051379:Mice; D008822:Mice, Transgenic; D010049:Ovarian Diseases / Q000209:etiology* / Q000503:physiopathology; D010051:Ovarian Neoplasms / Q000209:etiology / Q000503:physiopathology; D010053:Ovary / Q000503:physiopathology; D010446:Peptide Fragments / Q000235:genetics; D011085:Polycystic Ovary Syndrome / Q000209:etiology / Q000503:physiopathology; D016649:Primary Ovarian Insufficiency / Q000209:etiology / Q000503:physiopathology; D011993:Recombinant Fusion Proteins
D018997:Chorionic Gonadotropin, beta Subunit, Human; D037101:Luteinizing Hormone, beta Subunit; D010446:Peptide Fragments; D011993:Recombinant Fusion Proteins; D007986:Luteinizing Hormone